|
|
|
|
| LEADER |
01578nam a2200313 u 4500 |
| 001 |
EB000943952 |
| 003 |
EBX01000000000000000737542 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 020 |
|
|
|a 9780309218139
|
| 020 |
|
|
|a 9780309218146
|
| 020 |
|
|
|a 0309218136
|
| 245 |
0 |
0 |
|a Ethical and scientific issues in studying the safety of approved drugs
|h Elektronische Ressource
|c Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies
|
| 260 |
|
|
|a Washington, D.C.
|b National Academies Press
|c 2012, c2012
|
| 300 |
|
|
|a xvi, 275 p.
|b ill
|
| 505 |
0 |
|
|a Incorporating benefit and risk assessment and benefit/risk management into food and drug administration decision-making -- Evidence and decision-making -- Selection and oversight of required postmarketing studies -- Synthesis
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Product Surveillance, Postmarketing / methods
|
| 653 |
|
|
|a United States
|
| 653 |
|
|
|a Drug Evaluation / ethics
|
| 653 |
|
|
|a Clinical Trials as Topic / ethics
|
| 653 |
|
|
|a Drug Approval
|
| 710 |
2 |
|
|a Institute of Medicine (U.S.)
|b Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK200905
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 658
|
| 082 |
0 |
|
|a 170
|